Semaglutide effectiveness in real-world Type 2 Diabetes patients studied in Denmark and Sweden

Type 2 Diabetes (T2D) is a chronic metabolic condition requiring effective long-term management to prevent complications. While clinical trials establish efficacy under controlled conditions, real-world data is crucial to understand how treatments perform in diverse patient populations and routine clinical practice. Semaglutide, a GLP-1R agonist, has demonstrated significant benefits in T2D management, but its effectiveness and patient experience in local clinical settings across different regions warrant further investigation. This study aims to bridge that gap by observing its use in Denmark and Sweden.

This was a multi-center, prospective, non-interventional observational study conducted in Denmark and Sweden. Participants with Type 2 Diabetes receiving semaglutide as part of their routine clinical care were enrolled. The study aimed to collect real-world data on semaglutide effectiveness and patient experience over a 6 to 8 month period. Patients completed health and diabetes treatment questionnaires during their normally scheduled clinic visits. No specific dose or route was mandated beyond "semaglutide prescribed by the study doctor"; there was no control arm.